Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP   US8649091068

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
18.1(c) 17.72(c) 16.84(c) 14(c) 14.5(c) Last
273 321 170 619 347 307 2 704 174 1 240 944 Volume
+1.17% -2.10% -4.97% -16.86% +3.57% Change
More quotes
Financials ($)
Sales 2015 133 M
EBIT 2015 43,7 M
Net income 2015 28,1 M
Finance 2015 59,9 M
Yield 2015 -
Sales 2016 151 M
EBIT 2016 55,1 M
Net income 2016 36,6 M
Finance 2016 104 M
Yield 2016 -
PER 2015 25,34
PER 2016 19,15
EV / Sales 2015 4,42x
EV / Sales 2016 3,59x
Capitalization 647 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies.Prostones are naturally occurring fatty acid metabolites with unique physiological... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
03/26 SUCAMPO PHARMACEUTICALS : Announces Proposed Public Offering by Selling Stockhol..
03/26 Sucampo Prices Public Offering of Common Stock by Selling Stockholders
03/25 Sucampo Announces Proposed Public Offering by Selling Stockholders
03/10 SUCAMPO PHARMACEUTICALS : to Return All Licenses for Unoprostone Isopropyl to R-..
03/10 SUCAMPO PHARMACEUTICALS : Regulation FD Disclosure, Financial Statements and Exh..
03/09 SUCAMPO PHARMACEUTICALS : to Return All Licenses for Unoprostone Isopropyl to R-..
03/04 SUCAMPO PHARMACEUTICALS : posts 4Q profit
03/04 SUCAMPO PHARMACEUTICALS : Results of Operations and Financial Condition, Regulat..
More news
Sector news : Bio Therapeutic Drugs
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/26 Midday Gainers / Losers
03/26 Sucampo prices equity offering
03/26 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
03/26 Sucampo off 14% premarket on pending stock sales by shareholders
03/25 After Hours Gainers / Losers


Comments 
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF